EBIT Margin: Earnings before interest and taxes as a portion of total revenues. Calculated as: EBIT / Total Revenues
Bolt Biotherapeutics, Inc. (BOLT) had EBIT Margin of -510.53% for the most recently reported fiscal quarter, ending 2025-06-30.
| Income Statement Financials | |
$1.80M |
|
$-8.56M |
|
-- |
|
$1.80M |
|
$11.01M |
|
$-9.21M |
|
$0.65M |
|
$-8.56M |
|
$-8.56M |
|
$-8.56M |
|
$-8.56M |
|
$-8.56M |
|
$-8.56M |
|
$-9.21M |
|
$-9.03M |
|
1.92M |
|
1.92M |
|
$-4.46 |
|
$-4.46 |
|
| Balance Sheet Financials | |
$38.34M |
|
$1.72M |
|
$37.16M |
|
$75.50M |
|
$12.31M |
|
$21.62M |
|
$24.35M |
|
$36.66M |
|
$38.84M |
|
$38.84M |
|
$38.84M |
|
1.92M |
|
| Cash Flow Statement Financials | |
$-22.96M |
|
$25.34M |
|
$0.01M |
|
$8.97M |
|
$11.37M |
|
$2.40M |
|
$1.33M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
3.11 |
|
-- |
|
-- |
|
0.36 |
|
0.56 |
|
100.00% |
|
-510.53% |
|
|
EBIT Margin |
-510.53% |
-- |
|
-474.56% |
|
-474.56% |
|
$-22.00M |
|
-- |
|
-- |
|
-- |
|
0.02 |
|
-- |
|
-- |
|
-- |
|
-22.04% |
|
-22.04% |
|
-11.34% |
|
-14.16% |
|
$20.24 |
|
$-11.47 |
|
$-11.97 |
|